Thursday 27 April 2017 The one stop source for free breaking news, expert analysis, and videos on AIM and LSE listed shares


Optibiotix – Nizo Update: Upgrade, last chance to buy (we are 50% ahead already)

By HotStockRockets | Saturday 15 November 2014


Disclosure: Financial Investigative Media Limited, which is not owned by Tom Winnifrith but by a trust for his dependants, owns shares in companies mentioned in this article. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


OptiBiotix Health (OPTI) has announced positive results of trials of its anti-obesity compounds in fruit yoghurts in tests carried out by its Dutch partner Nizo.  The trials showed clearly that adding the compounds did not impact on taste, texture, etc.

The next step is to ensure all patent filings are correct before discussing manufacturing deals with partners.  In other words we are on the way to commercialisation. These deals could be big – certainly for a company which – at 14-14.25p is still only capitalised at £10 million and still has £3 million of cash.

To illustrate that point of what recent licensing deals for cholesterol reducing products – a similar market – are worth. Consider BioGaia licensing its Lactobacillus reuteri strain to Nestle for €50.8 million (Feb 2012) and Schiff Nutritions $40 million (2011) deal for Ganeden’s Bacillus coagulans BC30 strain.

For Optibiotix, we are aware that preliminary discussions with AB Bio, Du Pont, and Probiotics International suggest early commercial interest.

Other deals in the area of weight management if Optibiotix wants to go down the co-development route are Plandai’s £2 million upfront plus 5% of future revenues deal with Phyto Nutricare (April, 2013), and Trovita Healthcares product formulation licensing deal with Galen (Aug, 2013). Again we are told that preliminary discussions with ingredient manufacturers suggest early commercial interest.

Of course there are risks but with a strong balance sheet, a cracking management team and the news from Nizo you ca see the upside.

We tipped this at 9p a few months ago with an initial limit buy price of 12p and 24p target. We now increase the limit buy price to 15p and our target is now 30p. Buy ahead of the next news which we think is imminent.

To catch the next hit tip on HotStockRockets for just £5 click HERE

 


Filed under:


Never miss a story.




This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.


More on OPTI


Comments

2 comments

  1. I thought the human trials results did not even publish until the end end of Q3 2015 ?

  2. You did say, Tom.


Enter your comment below. Fields marked * are required. You must preview your comment first before finally posting.




Site by Everywhen